Can sesame consumption improve blood pressure? A systematic review and meta-analysis of controlled trials
Hossein Khosravi-Boroujeni
Menzies Health Institute Queensland & School of Medicine, Griffith University, Gold Coast, QLD, Australia
Search for more papers by this authorElham Nikbakht
Menzies Health Institute Queensland & School of Medical Science, Griffith University, Gold Coast, QLD, Australia
Search for more papers by this authorErnesta Natanelov
Menzies Health Institute Queensland & School of Medicine, Griffith University, Gold Coast, QLD, Australia
Search for more papers by this authorCorresponding Author
Saman Khalesi
School of Health, Medical and Applied Sciences, Central Queensland University, Rockhampton, QLD, Australia
Correspondence to: S Khalesi, School of Health, Medical and Applied Sciences, Central Queensland University, Rockhampton, QLD, Australia. E-mail: [email protected]Search for more papers by this authorHossein Khosravi-Boroujeni
Menzies Health Institute Queensland & School of Medicine, Griffith University, Gold Coast, QLD, Australia
Search for more papers by this authorElham Nikbakht
Menzies Health Institute Queensland & School of Medical Science, Griffith University, Gold Coast, QLD, Australia
Search for more papers by this authorErnesta Natanelov
Menzies Health Institute Queensland & School of Medicine, Griffith University, Gold Coast, QLD, Australia
Search for more papers by this authorCorresponding Author
Saman Khalesi
School of Health, Medical and Applied Sciences, Central Queensland University, Rockhampton, QLD, Australia
Correspondence to: S Khalesi, School of Health, Medical and Applied Sciences, Central Queensland University, Rockhampton, QLD, Australia. E-mail: [email protected]Search for more papers by this authorAbstract
Hypertension is a major risk factor for cardiovascular disease, myocardial infarction, stroke and renal failure. Sesame consumption may benefit blood pressure (BP) owing to its high polyunsaturated fatty acid, fibre, phytosterol and lignan contents. To clarify this, a systematic review and meta-analysis of controlled trials was conducted. The PubMed (MEDLINE), Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Cochrane Library (Central) databases were systematically searched until August 2016. Eight controlled trials with a total of 843 participants met the eligibility criteria. A random effect meta-analysis showed that sesame consumption can reduce systolic BP (−7.83 mmHg, 95% CI: −14.12, −1.54; P < 0.05, I2 = 99%) and diastolic BP (−5.83 mmHg, 95% CI: −9.58, −2.08; P < 0.01, I2 = 98%). To reduce the heterogeneity, the meta-analysis was limited to high methodology quality trials (n = 4), which resulted in a significant reduction in systolic BP (−3.23 mmHg, 95% CI: −5.67, −0.79; I2 = 33%) and a non-significant reduction in diastolic BP (−2.08 mmHg, 95% CI: −4.85, 0.69; I2 = 62%). This study concluded that sesame consumption can reduce systolic and diastolic BP. However, further investigations with larger sample sizes and better methodology quality are required to confirm the BP-lowering effect of sesame consumption. © 2017 Society of Chemical Industry
Supporting Information
Filename | Description |
---|---|
jsfa8361-sup-0001-AppendixS1.docxWord 2007 document , 20 KB | Supplemental Table 1. Methodology assessment summary and Rosendal score of included studies Supplemental Table 2. Results of sensitivity analysis using alternative levels of correlation coefficient (r) associated with sesame consumption analysis Supplemental Table 3. Post-intervention systolic and diastolic blood pressure for included studies. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Ong KL, Cheung BMY, Man YB, Lau CP and Lam KSL, Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 49: 69–75 (2007).
- 2Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK and He J, Global burden of hypertension: analysis of worldwide data. Lancet 365: 217–223 (2005).
- 3Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S et al., Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension. J Hypertens 30: 239–252 (2012).
- 4Sacks FM and Campos H, Dietary therapy in hypertension. New Engl J Med 362: 2102–2112 (2010).
- 5Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al., Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206–1252 (2003).
- 6Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al., Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens 16: 14–26 (2014).
- 7Diao D, Wright JM, Cundiff DK and Gueyffier F, Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev (8):CD006742 (2012).
- 8Gascón JJ, Sánchez-Ortuño M, Llor B, Skidmore D and Saturno PJ, Why hypertensive patients do not comply with the treatment: results from a qualitative study. Fam Pract 21: 125–130 (2004).
- 9Gee ME, Janssen I, Pickett W, McAlister FA, Bancej CM, Joffres M et al., Prevalence, awareness, treatment, and control of hypertension among Canadian adults with diabetes, 2007 to 2009. Can J Cardiol 28: 367–374 (2012).
- 10Shantakumari N, Eldeeb RA, Mabrouk Ibrahim SA, Sreedharan J and Otoum S, Effect of PUFA on patients with hypertension: a hospital based study. Indian Heart J 66: 408–414 (2014).
- 11Fischer R, Dechend R, Qadri F, Markovic M, Feldt S, Herse F et al., Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension 51: 540–546 (2008).
- 12Frenoux J-MR, Prost ED, Belleville JL and Prost JL, A polyunsaturated fatty acid diet lowers blood pressure and improves antioxidant status in spontaneously hypertensive rats. J Nutr 131: 39–45 (2001).
- 13Pezeshk A and Dalhouse AD, Vitamin E, membrane fluidity, and blood pressure in hypertensive and normotensive rats. Life Sci 67: 1881–1889 (2000).
- 14Boshtam M, Rafiei M, Sadeghi K and Sarraf-Zadegan N, Vitamin E can reduce blood pressure in mild hypertensives. Int J Vitam Nutr Res 72: 309–314 (2002).
- 15Laight DW, Carrier MJ and Änggård EE, Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res 47: 457–464 (2000).
- 16Palumbo G, Avanzini F, Alli C, Roncaglioni MC, Ronchi E, Cristofari M et al., Effects of vitamin E on clinic and ambulatory blood pressure in treated hypertensive patients. Am J Hypertens 13: 564–567 (2000).
- 17Young IS and Woodside JV, Antioxidants in health and disease. J Clin Pathol 54: 176–186 (2001).
- 18Elleuch M, Besbes S, Roiseux O, Blecker C and Attia H, Quality characteristics of sesame seeds and by-products. Food Chem 103: 641–650 (2007).
- 19Kamal-Eldin A, Moazzami A and Washi S, Sesame seed lignans: potent physiological modulators and possible ingredients in functional foods & nutraceuticals. Recent Pat Food Nutr Agric 3: 17–29 (2011).
- 20Matsumura Y, The anti-hypertensive effect of sesamin, in Novel Compounds from Natural Products in the New Millennium. Potential and Challenges, ed. by BK-H Tan, B-H Bay and Y-Z Zhu. World Scientific, Singapore, pp. 170–182 (2004).
10.1142/9789812562210_0016 Google Scholar
- 21Kita S, Matsumura Y, Morimoto S, Akimoto K, Furuya M, Oka N et al., Antihypertensive effect of sesamin. II. Protection against two-kidney, one-clip renal hypertension and cardiovascular hypertrophy. Biol Pharmaceut Bull 18: 1283–1285 (1995).
- 22Noguchi T, Ikeda K, Sasaki Y, Yamamoto J, Seki J, Yamagata K et al., Effects of vitamin E and sesamin on hypertension and cerebral thrombogenesis in stroke-prone spontaneously hypertensive rats. Hypertens Res 24: 735–742 (2001).
- 23Namiki M, Nutraceutical functions of sesame: a review. Crit Rev Food Sci Nutr 47: 651–673 (2007).
- 24Nakano D, Itoh C, Takaoka M, Kiso Y, Tanaka T and Matsumura Y, Antihypertensive effect of sesamin. IV. Inhibition of vascular superoxide production by sesamin. Biol Pharmaceut Bull 25: 1247–1249 (2002).
- 25Lee C-C, Chen P-R, Lin S, Tsai S-C, Wang B-W, Chen W-W et al., Sesamin induces nitric oxide and decreases endothelin-1 production in HUVECs: possible implications for its antihypertensive effect. J Hypertens 22: 2329–2338 (2004).
- 26Wu JHY, Hodgson JM, Puddey IB, Belski R, Burke V and Croft KD, Sesame supplementation does not improve cardiovascular disease risk markers in overweight men and women. Nutr Metabol Cardiovasc Dis 19: 774–780 (2009).
- 27Sankar D, Rao MR, Sambandam G and Pugalendi KV, Effect of sesame oil on diuretics or β-blockers in the modulation of blood pressure, anthropometry, lipid profile, and redox status. Yale J Biol Med 79: 19–26 (2006).
- 28Sankar D, Rao MR, Sambandam G and Pugalendi KV, A pilot study of open label sesame oil in hypertensive diabetics. J Med Food 9: 408–412 (2006).
- 29Chen P-R, Tsai CE, Chang H, Liu T-L and Lee C-C, Sesamol induces nitric oxide release from human umbilical vein endothelial cells. Lipids 40: 955–961 (2005).
- 30Wichitsranoi J, Weerapreeyakul N, Boonsiri P, Settasatian C, Settasatian N, Komanasin N et al., Antihypertensive and antioxidant effects of dietary black sesame meal in pre-hypertensive humans. Nutr J 10: 82 (2011).
- 31Khajehdehi P, Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. J Renal Nutr 10: 191–195 (2000).
- 32Moher D, Liberati A, Tetzlaff J and Altman DG, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264–269 (2009).
- 33Van Rosendal SP, Osborne MA, Fassett RG and Coombes JS, Guidelines for glycerol use in hyperhydration and rehydration associated with exercise. Sports Med 40: 113–139 (2010).
- 34 JPT Higgins and S Green (eds), Cochrane Handbook for Systematic Reviews of Interventions. Wiley-Blackwell, Oxford (2008).
- 35Follmann D, Elliott P, Suh I and Cutler J, Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45: 769–773 (1992).
- 36DerSimonian R and Laird N, Meta-analysis in clinical trials. Contr Clin Trials 7: 177–188 (1986).
- 37Helli B, Mowla K, Mohammadshahi M and Jalali MT, Effect of sesamin supplementation on cardiovascular risk factors in women with rheumatoid arthritis. J Am Coll Nutr 35: 300–307 (2016).
- 38Sankar D, Sambandam G, Rao MR and Pugalendi KV, Modulation of blood pressure, lipid profiles and redox status in hypertensive patients taking different edible oils. Clin Chim Acta 355: 97–104 (2005).
- 39Miyawaki T, Aono H, Toyoda-Ono Y, Maeda H, Kiso Y and Moriyama K, Antihypertensive effects of sesamin in humans. J Nutr Sci Vitaminol 55: 87–91 (2009).
- 40Stamler J, Rose G, Stamler R, Elliott P, Dyer A and Marmot M, INTERSALT study findings. Public health and medical care implications. Hypertension 14: 570–577 (1989).
- 41Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M et al., The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 32: 3–107 (2009).
- 42Matsumura Y, Kita S, Tanida Y, Taguchi Y, Morimoto S, Akimoto K et al., Antihypertensive effect of sesamin. III. Protection against development and maintenance of hypertension in stroke-prone spontaneously hypertensive rats. Biol Pharmaceut Bull 21: 469–473 (1998).
- 43Nakano D, Kwak C-J, Fujii K, Ikemura K, Satake A, Ohkita M et al., Sesamin metabolites induce an endothelial nitric oxide-dependent vasorelaxation through their antioxidative property-independent mechanisms: possible involvement of the metabolites in the antihypertensive effect of sesamin. J Pharmacol Exp Therapeut 318: 328–335 (2006).
- 44Nakano D, Itoh C, Ishii F, Kawanishi H, Takaoka M, Kiso Y et al., Effects of sesamin on aortic oxidative stress and endothelial dysfunction in deoxycorticosterone acetate-salt hypertensive rats. Biol Pharmaceut Bull 26: 1701–1705 (2003).
- 45Nakai M, Harada M, Nakahara K, Akimoto K, Shibata H, Miki W et al., Novel antioxidative metabolites in rat liver with ingested sesamin. J Agric Food Chem 51: 1666–1670 (2003).
- 46Zalba G, San José G, Moreno MU, Fortuño MA, Fortuño A, Beaumont FJ et al., Oxidative stress in arterial hypertension. Role of NAD(P)H oxidase. Hypertension 38: 1395–1399 (2001).
- 47Kushiro M, Takahashi Y and Ide T, Species differences in the physiological activity of dietary lignan (sesamin and episesamin) in affecting hepatic fatty acid metabolism. Br J Nutr 91: 377–386 (2004).
- 48Zhang X and Ellis EF, Superoxide dismutase reduces permeability and edema induced by hypertension in rats. Am J Physiol 259: H497–H503 (1990).
- 49Ito H, Torii M and Suzuki T, Decreased superoxide dismutase activity and increased superoxide anion production in cardiac hypertrophy of spontaneously hypertensive rats. Clin Exp Hypertens 17: 803–816 (1995).
- 50Niki E, Yoshida Y, Saito Y and Noguchi N, Lipid peroxidation: mechanisms, inhibition, and biological effects. Biochem Biophys Res Commun 338: 668–676 (2005).
- 51Catapano AL, Farnier M, Foody JM, Toth PP, Tomassini JE, Brudi P et al., Combination therapy in dyslipidemia: where are we now? Atherosclerosis 237: 319–335 (2014).
- 52Ito H, Torii M and Suzuki T, Comparative study on free radical injury in the endothelium of SHR and WKY aorta. Clin Exp Pharmacol Physiol 22(Suppl. s1): S157–S159 (1995).
- 53Thomas SR, Chen K and Keaney Jr JF, Oxidative stress and endothelial nitric oxide bioactivity. Antioxid Redox Signal 5: 181–194 (2003).
- 54Schiffrin EL and Deng L-Y, Comparison of effects of angiotensin I-converting enzyme inhibition and β-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 25: 699–703 (1995).
- 55Fitch RM, Vergona R, Sullivan ME and Wang Y-X, Nitric oxide synthase inhibition increases aortic stiffness measured by pulse wave velocity in rats. Cardiovasc Res 51: 351–358 (2001).
- 56McEniery CM, Qasem A, Schmitt M, Avolio AP, Cockcroft JR and Wilkinson IB, Endothelin-1 regulates arterial pulse wave velocity in vivo. J Am Coll Cardiol 42: 1975–1981 (2003).
- 57Wu JHY, Hodgson JM, Clarke MW, Indrawan AP, Barden AE, Puddey IB et al., Inhibition of 20-hydroxyeicosatetraenoic acid synthesis using specific plant lignans. In vitro and human studies. Hypertension 54: 1151–1158 (2009).
- 58Carroll MA and McGiff JC, A new class of lipid mediators: cytochrome P450 arachidonate metabolites. Thorax 55(Suppl. 2): S13–S16 (2000).
- 59Clandinin MT, Cheema S, Field CJ, Garg ML, Venkatraman J and Clandinin TR, Dietary fat: exogenous determination of membrane structure and cell function. FASEB J 5: 2761–2769 (1991).
- 60Singer P, Berger I, Moritz V, Förster D and Taube C, N-6 and N-3 PUFA in liver lipids, thromboxane formation and blood pressure from SHR during diets supplemented with evening primrose, sunflowerseed or fish oil. Prostaglandins Leukot Essent Fatty Acids 39: 207–211 (1990).
- 61Delerive P, Oudot F, Ponsard B, Talpin S, Sergiel JP, Cordelet C et al., Hypoxia-reoxygenation and polyunsaturated fatty acids modulate adrenergic functions in cultured cardiomyocytes. J Mol Cell Cardiol 31: 377–386 (1999).
- 62Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA and Willett WC, Vitamin E consumption and the risk of coronary heart disease in men. New Engl J Med 328: 1450–1456 (1993).
- 63McCord JM and Fridovich I, Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244: 6049–6055 (1969).
- 64Kamal-Eldin A, Frank J, Razdan A, Tengblad S, Basu S and Vessby B, Effects of dietary phenolic compounds on tocopherol, cholesterol, and fatty acids in rats. Lipids 35: 427–435 (2000).